The healthcare landscape is undergoing a period of significant adjustment, marked by fluctuating financial performance and strategic realignment among major players. Elevance Health, one of the nation’s largest health insurers, is responding to these pressures with a restructuring of its C-suite, consolidating control of its health insurance businesses under Felicia Norwood, currently head of government benefits. This move comes as the company navigates challenges including flagging margins in government programs and a shifting economic outlook, and follows the departure of a key executive from its Carelon division.
The changes, announced Thursday, spot Norwood assuming a broader role overseeing Elevance’s Medicaid, Medicare, and commercial health plans. Simultaneously, Mark Kaye, Elevance’s Chief Financial Officer, will expand his responsibilities to include leadership of Carelon, the company’s health services division. These shifts occur as Peter Haytaian, the current president of Carelon, prepares to step down on May 4th, remaining as an advisor through the end of the year. The restructuring signals a strategic effort to improve coordination across Elevance’s diverse portfolio and potentially bolster profitability in a challenging market.
Elevance Responds to Market Pressures
Like many of its competitors, Elevance Health is facing headwinds in the form of shrinking profit margins, particularly within government-sponsored healthcare programs. Industry predictions suggest continued pressure on these margins due to rising medical utilization costs coupled with what insurers perceive as inadequate reimbursement rates from Medicare, and Medicaid. The expiration of enhanced Affordable Care Act (ACA) subsidies, previously implemented by Congress, is also expected to exacerbate these financial strains. These subsidies, which provided more generous financial assistance for ACA coverage, were allowed to lapse, potentially increasing costs for consumers and impacting insurer enrollment numbers.
Elevance’s financial outlook reflects these challenges. In January, the company informed investors that it anticipates a decline in both revenue and profit in 2026. This announcement triggered a significant drop in the company’s stock price, which remains down 10% year-to-date as of February 28, 2026. Despite these short-term concerns, Elevance maintains confidence in its long-term growth prospects, largely attributing this optimism to the continued strong performance of Carelon.
Carelon’s Role in Elevance’s Strategy
Carelon, Elevance’s health services division, has emerged as a key component of the company’s growth strategy. Elevance has been actively investing in strengthening Carelon’s capabilities, particularly within the pharmacy sector. Last year, the company added two experienced pharmaceutical industry veterans, Amy Schulman and David Ricks, to its board of directors, demonstrating a commitment to expanding its presence in this lucrative market. The division has consistently outperformed expectations in terms of revenue and earnings growth, positioning it as a crucial driver of future profitability for Elevance.
The appointment of Felicia Norwood as Elevance’s first Chief Health Benefits Officer and the assignment of oversight of Carelon to Mark Kaye are intended to streamline operations and enhance coordination across the organization. According to Elevance CEO Gail Boudreaux, these changes will “support disciplined execution and facilitate us move with greater clarity and coordination as we continue to scale.” This suggests a focus on integrating Carelon’s services more seamlessly with Elevance’s insurance offerings, potentially creating a more comprehensive and efficient healthcare delivery system.
Executive Transitions and Backgrounds
The departure of Peter Haytaian marks the end of a nearly decade-long tenure with Elevance. Haytaian initially joined the company in 2012 through the acquisition of Amerigroup, and subsequently rose through the ranks to become president of Carelon in 2021. His decision to leave the role is reportedly motivated by a desire to spend more time with his family. He will remain with the company as an advisor through the end of 2026, ensuring a smooth transition of leadership.
Felicia Norwood brings extensive experience in both the healthcare industry and the government sector to her expanded role. Currently serving as Executive Vice President and President of Government Health Benefits at Elevance Health, she oversees the company’s Medicaid and Medicare businesses, serving over 46 million people across the United States. Her background also includes a prior role as Director of Illinois’ Department of Healthcare and Family Services, as well as senior leadership positions at Aetna, including President of Aetna Government Health Plans.
Mark Kaye, as CFO, has been instrumental in Elevance’s financial strategy. Expanding his responsibilities to include Carelon will likely involve a closer integration of financial planning and resource allocation between the insurance and health services divisions. His leadership will be critical in navigating the financial challenges facing the industry and maximizing the potential of Carelon’s growth.
Key Takeaways
- Strategic Realignment: Elevance Health is restructuring its leadership to improve coordination and address financial pressures.
- Carelon’s Importance: The health services division is positioned as a key driver of future growth for the company.
- Executive Departure: Peter Haytaian is leaving his role as president of Carelon to pursue personal priorities.
- Norwood’s Expanded Role: Felicia Norwood will oversee all of Elevance’s health benefits programs, leveraging her extensive experience in government healthcare.
The changes at Elevance Health reflect a broader trend within the healthcare industry, as insurers grapple with rising costs, evolving regulations, and the necessitate to innovate in order to remain competitive. The company’s focus on integrating its insurance and health services offerings, coupled with its investment in Carelon, suggests a long-term strategy aimed at delivering more comprehensive and coordinated care to its members. The success of this strategy will depend on the ability of the new leadership team to navigate the complex challenges facing the industry and capitalize on emerging opportunities.
Elevance Health’s next major financial update is scheduled for its first-quarter earnings call in May 2026, where investors will be closely watching for further details on the implementation of these changes and their impact on the company’s performance. The company’s ability to demonstrate progress in improving coordination, controlling costs, and driving growth will be crucial in restoring investor confidence and positioning Elevance for long-term success.
What are your thoughts on these changes at Elevance Health? Share your insights and perspectives in the comments below. Don’t forget to share this article with your network to maintain the conversation going.
Worth a look